Trulieve reports $230 million revenue for third quarter 2026
Trulieve posted $230 million in revenue for the third quarter of 2026, supported by a 64% gross margin and significant operational cash flow.
Trulieve released its financial results for the third quarter of 2026, reporting revenue of $230 million and a gross margin of 64%. The results arrive as the company manages shifting regulatory landscapes in the cannabis sector.
Financial data for the first nine months of the year shows $183 million in cash flow from operations, alongside a free cash flow of $120 million. These figures indicate the company's focus on capital preservation and operational efficiency within the medical marijuana market.
A key development for the company is the receipt of final DEA registrations following the federal decision to reschedule state-licensed medical marijuana to Schedule III. This classification change represents a shift in federal policy that could alter compliance requirements and operational frameworks for companies operating across state lines.
As the industry adjusts to these federal shifts, Trulieve remains focused on its established market positions while monitoring further regulatory updates.